Glaukos Corporation (GKOS)

From the record

Glaukos Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Glaukos Corporation's 10 filed years say what it did: revenue went from $114 million in fiscal 2016 to $507 million in fiscal 2025, up 18% a year; it rose in 7 of 9 years; the deepest fall was 5% from fiscal 2019 to fiscal 2020; net income was positive in 2 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Glaukos Corporation lost about 29 cents for every dollar of shareholders' money, and gross profitability: its products earned about 32 cents per dollar of everything the company owns. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 8.4% over the year (the filed statements).

From the record

Glaukos Corporation's standing among 109 graded names in its industry family: revenue of $507 million in fiscal 2025 ranks in the top 28% by size; a net margin of -37% ranks in the bottom 40%; revenue growth of 21.5% a year over the last 3 filed years ranks in the top 36% (its annual reports).

From the record

Glaukos Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Burns, Thomas William (CHAIRMAN & CEO, as filed), filing under that title since 2015-06-24, 11.4 years (top 16% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 11.4 years (top 6%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 2%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Glaukos Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $91 million against no long-term debt tagged leaves 10.2% of its assets as net cash, bottom 48% of its family; cash from operations less capital spending is -4.4% of revenue (top 48%); a gross margin of 55.7% (bottom 39%); research spending of 29.7% of revenue (top 30%) (its annual report).

From the record

Glaukos Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 21.5% a year over the last three filed years against 18% over all 10, speeding up (top 22% of its family); the newest year grew 32.4% (top 21%); research spending grew 6.9% a year (top 47%); capital spending grew -36.7% a year (bottom 13%) (its annual reports). Glaukos Corporation reported 2 product lines in fiscal 2025: Glaucoma at $421 million (83%), Corneal Health at $86 million (17%); 2 of 2 grew against the year before (its annual report).

From the record

Glaukos Corporation's newest year against its own record: revenue of $507 million in fiscal 2025 came in 13.7% above the $446 million its prior three years' pace pointed to (top 12% of its family); net income of $188 million against a prior three-year average of $127 million (bottom 17%); a net margin of -37% against -38.7% before (bottom 31%) (its annual reports).